Stocks · News reference
Lantheus receives FDA approval for PET imaging agent used to evaluate adults for Alzheimer's disease by identifying tau pathology.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better
Read original at benzingaLantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.30 by 19.23 percent. This is a 1.27 percent decrease over earnings of $1.57 per share from
Read original at benzingaHalper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.
Read original at globenewswire-inc